Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment
NCT02512627, Not applicable, Completed, Chang Gung Memorial Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT02512627 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 55 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Chang Gung Memorial Hospital | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Cognitive training, Physical exercise | ClinicalTrials.gov |
| First posted | 2015-07-31 | ClinicalTrials.gov |
| Last updated | 2019-07-12 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change scores of Montreal Cognitive Assessment (MoCA) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The MoCA will be used to assess general cognitive functions. It examines several cognitive domains with a total score of 30. | ClinicalTrials.gov |
| Primary | Change scores of Stroop test | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The Stroop test will be used to assess the processing speed, inhibition, set-shifting, and selective attention abilities. The participants will be tested under 2 conditions: congruent and incongruent conditions. In the congruent condition, the color ink of a word is consistent with the written color name; while the color ink differs from the written color name under the incongruent condition. | ClinicalTrials.gov |
| Primary | Change scores of Dual-task test | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The dual-task tests will be assessed to determine the ability for an individual to perform 2 tasks simultaneously. The investigators will assess the dual-task performance during walking and performing box and block test. The results of the dual-task tests will provide information regarding to whether the 2 tasks compete for the same class of neural resources or one of the tasks can be carried out automatically. | ClinicalTrials.gov |
| Primary | Change scores of Timed up and go (TUG) test | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The TUG test will be used to assess the mobility and dynamic balance ability. The participants will be required to stand up from a chair, walk 3 meters, turn around, then walk back to the chair, and sit down. The time to complete the TUG test has been shown to be a good indicator to detect potential fallers and frail elderly (Podsiadlo \& Richardson, 1991). The test-retest reliability of TUG on individuals with cognitive impairment was excellent (Blankevoort, van Heuvelen, \& Scherder, 2013). | ClinicalTrials.gov |
| Secondary | Change scores of the Verbal Fluency Test | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | Verbal fluency tests will be used to evaluate the semantic memory of the participants. The participants will be instructed to say as many words as possible from a given category (i.e., fruit or animal) in 1 minute. The validity, reliability, and normative performance of verbal fluency tests have been well-established (Harrison, Buxton, Husain, \& Wise, 2000). | ClinicalTrials.gov |
| Secondary | Change scores of the Useful Field of View (UFOV) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | Useful field of view (UFOV) is the visual area over which useful information could be obtained at a quick glance without eye or head movements. This UFOV will be assessed with the BrainHQ program. The UFOV will assess the abilities of visuomotor processing speed, divided attention, and selective attention (Ball, Edwards, \& Ross, 2007). | ClinicalTrials.gov |
| Secondary | Change scores of the 30 second chair stand test (CST) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The 30 second chair stand test (CST) will be assessed to indicate the strength and endurance level of the lower extremities. The participants will be asked to stand up from a standardized chair and then sit down as many times as possible within 30 seconds. The feasibility and reliability of using CST in people with cognitive impairment have been established to be good (Blankevoort et al., 2013). | ClinicalTrials.gov |
| Secondary | Change scores of the Chinese version of the International Physical Activity Questionnaires (IPAQ) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The Chinese version of the International Physical Activity Questionnaires (IPAQ) is an international measure for health-related physical activity. A short form of IPAQ will be used to assess changes in physical activity before and after intervention in this study. The reliability and validity of IPAQ has been established across 12 countries (Craig et al., 2003). | ClinicalTrials.gov |
| Secondary | Change scores of the Barthel Index (BI) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | Assess activities of daily living | ClinicalTrials.gov |
| Secondary | Change scores of the Lawton Instrumental Activities of Daily Living Scale | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | Assess activities of daily living. | ClinicalTrials.gov |
| Secondary | Change scores of the Disability Assessment for Dementia (DAD) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | Assess activities of daily living. | ClinicalTrials.gov |
| Secondary | Change scores of the Quality of Life in Alzheimer's Disease Instrument (QoLAD) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The Chinese version of QoLAD will be used. | ClinicalTrials.gov |
| Secondary | Change scores of the Caregiver Burden Inventory (CBI) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The Chinese version of CBI will be used. | ClinicalTrials.gov |
| Secondary | Change scores of the Geriatric Depression Scale (GDS) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The Chinese version of short form GDS will be used. | ClinicalTrials.gov |
| Secondary | Change scores of the Community Integration Questionnaire (CIQ) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The CIQ measures items relevant to home integration, social integration, and productive activities. | ClinicalTrials.gov |
| Secondary | Change scores of the ActiGraph GX3 accelerometers Change scores of the ActiGraph | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The actigraphy will be placed on the waist for a 3-day period immediately before and after the intervention. The participants will wear the actigraphy during all daily activities except for those that involve water (i.e., showering or swimming). | ClinicalTrials.gov |
| Secondary | Change scores of evaluating isometric knee flexors and extensors muscle strength | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The participant will be seated upright in a chair with back support, the knee will be placed in 90-degree flexion and the evaluator will stabilize the thing to eliminate synergistic movements. Participants will be asked to perform a maximal isometric contraction of knee flexion and extension with both lower extremities. The investigators will record the mean value of 3 attempts. | ClinicalTrials.gov |
| Secondary | Change scores of using hand dynamometer to measure grip strength of both hand | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The participant is seated, with the elbow at 90-degree flexion. The investigators will record the mean value of 3 attempts. | ClinicalTrials.gov |
| Secondary | Change scores of Wechsler Memory Scale - Third Edition (WMS-III) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The investigators will use the WMS-III subtests, including Faces Recognition (score range 0-48), Verbal Paired Associates (score range 0-32), Word Lists (0-48), and Spatial Span (0-32) to assess the immediate, delayed, and working memory tests. Higher scores indicated better performance for each subtest. The raw score of each subtest will also be transferred to standardized Z scores and summed to represent an index of general memory function. | ClinicalTrials.gov |
| Secondary | Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III) | baseline, posttest (an expected average of 3 months), follow-up (up to 9 months) | The WAIS-III includes tests that evaluate cognitive functions in verbal comprehension, working memory, perceptual organization, and processing speed. The subtests that the investigators will use are the Digit Symbol-Coding (scores range 0-133) and Matrix Reasoning tests (0-26). The raw score of each subtest will also be transferred to standardized Z scores and summed to represent an index of general cognitive function. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 27793183 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Field of View Speed Test | Secondary outcome | ConductCognition |
| Matrix Reasoning | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Word Pair Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)